HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $57 Price Target
Rigel to Present at the Jefferies Global Healthcare Conference
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call - Slideshow
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $81
Rigel Pharmaceuticals, Inc. (RIGL) M&A Call Transcript
Arvinas: FDA Approval Validates The Platform, But Does Not Signal Near-Term Profitability
We Believe Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are A Poor Guide For Its Profitability
Rigel to Pay $85M Upfront for FDA-Approved VEPPANU; Potential $320M in Milestones Ahead
Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally
This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge
Citigroup Maintains Buy on Rigel Pharmaceuticals, Lowers Price Target to $69
Rigel Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Rigel Pharmaceuticals Q1 Earnings Call Highlights
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
Rigel Pharmaceuticals (NASDAQ:RIGL) Q1 2026 Results Miss Revenue and EPS Estimates, Stock Declines After-Hours
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
